KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Castle Biosciences (CSTL) EBIT (2018 - 2025)

Historic EBIT for Castle Biosciences (CSTL) over the last 8 years, with Q3 2025 value amounting to -$6.8 million.

  • Castle Biosciences' EBIT fell 23396.34% to -$6.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$34.9 million, marking a year-over-year decrease of 326541.43%. This contributed to the annual value of $8.7 million for FY2024, which is 11275.43% up from last year.
  • Per Castle Biosciences' latest filing, its EBIT stood at -$6.8 million for Q3 2025, which was down 23396.34% from -$4.3 million recorded in Q2 2025.
  • Castle Biosciences' 5-year EBIT high stood at $5.1 million for Q3 2024, and its period low was -$31.5 million during Q1 2023.
  • For the 5-year period, Castle Biosciences' EBIT averaged around -$11.1 million, with its median value being -$8.8 million (2021).
  • In the last 5 years, Castle Biosciences' EBIT crashed by 126589.15% in 2021 and then surged by 17158.01% in 2024.
  • Over the past 5 years, Castle Biosciences' EBIT (Quarter) stood at -$15.2 million in 2021, then crashed by 50.5% to -$22.8 million in 2022, then skyrocketed by 75.22% to -$5.7 million in 2023, then surged by 171.58% to $4.0 million in 2024, then plummeted by 268.0% to -$6.8 million in 2025.
  • Its EBIT was -$6.8 million in Q3 2025, compared to -$4.3 million in Q2 2025 and -$27.9 million in Q1 2025.